newsfilter
← Latest News
GlobeNewswire·

Trevi Therapeutics to Participate in Upcoming Events

TRVI
  • Trevi Therapeutics Inc. (NASDAQ: TRVI) announced that senior management will participate in upcoming investor events.
  • Jennifer Good (President & CEO) and David Hastings (CFO) will attend the 25th Annual Needham Virtual Healthcare Conference April 13-16, 2026, with a fireside chat on April 13.
  • Good & Hastings will present at the Raymond James 2026 Biotech Innovation Symposium in New York on April 14, 2026.
  • Good will represent Trevi at Oppenheimer's 2026 Innovation on the Island in Puerto Rico from April 27-29, 2026.
  • An Investor & Analyst Day is scheduled for May 7, 2026, in New York from 10:00 a.m. to 12:00 p.m. ET, featuring senior management & key opinion leaders.
  • The company is developing Haduvio (oral nalbuphine ER) as an investigational therapy for chronic cough in IPF, non-IPF ILD, & RCC.
  • Haduvio acts as a kappa agonist & mu antagonist (KAMA) & was the first investigational therapy to show statistically significant cough reduction in IPF & RCC trials.
  • Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
  • Approximately 150,000 U.S. patients have IPF, with two-thirds experiencing uncontrolled chronic cough, while 228,000 have non-IPF ILD with 50-60% having uncontrolled cough.
  • Roughly 2-3 million U.S. patients suffer from refractory chronic cough (RCC), defined as a persistent cough lasting over 8 weeks despite treatment for underlying conditions.
  • No FDA-approved therapies currently exist for chronic cough in IPF, non-IPF ILD, or RCC.
  • Haduvio has not yet been evaluated by any regulatory authority for safety or efficacy.
  • Trevi intends to use "Haduvio" as the trade name for oral nalbuphine ER.